Blood Grouping Reagent

Anti-\(\kappa\) (KEL2)
Seraclone® Murine Monoclonal (Lk1)

FOR IN-VITRO DIAGNOSTIC USE
For Tube Testing
MEETS FDA POTENCY REQUIREMENTS
U.S. License Number: 1798

Package size
REF 808125100 VOL 5 mL  Seraclone® Anti-\(\kappa\) (KEL2)

Intended Use
For the determination of the \(\kappa\) (KEL2) (Cellano) antigen of red blood cells using the tube test.

Summary
Since the description of the antigen K in 1946 by Coombs et al and its allele \(\kappa\) in 1949 by Levine et al, the Kell blood group system has been shown to be increasingly complex and over 20 antigens are now known to be associated with the system. These are probably controlled from a series of closely linked loci so that Kell antigens, like CDE in the Rh system, are inherited as haplotype.

The antigens of the Kell blood group system are of further interest in that they tend to occur either very frequently (eg \(\kappa\) 99.8%) or relatively infrequently (eg K 8%) and show considerable ethnic variation. Kell system antibodies are capable of causing hemolytic transfusion reactions (HTR) and hemolytic disease of the fetus and newborn (HDFN) and are optimally detected by the indirect antiglobulin technique.\(^1\)

The frequencies of the common phenotypes are shown in the table.

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>(\kappa+k^{-})</td>
<td>0.2</td>
<td>Rare</td>
</tr>
<tr>
<td>(\kappa+k^{+})</td>
<td>8.8</td>
<td>2</td>
</tr>
<tr>
<td>(K-k^{+})</td>
<td>91.0</td>
<td>98</td>
</tr>
<tr>
<td>(Kp (a+b^{-}))</td>
<td>Rare</td>
<td>0</td>
</tr>
<tr>
<td>(Kp (a+b^{+}))</td>
<td>2.3</td>
<td>Rare</td>
</tr>
<tr>
<td>(Kp (a-b^{-}))</td>
<td>97.7</td>
<td>100</td>
</tr>
<tr>
<td>(Js (a^{-}b^{+}))</td>
<td>0.0</td>
<td>1</td>
</tr>
<tr>
<td>(Js (a^{+}b^{-}))</td>
<td>Rare</td>
<td>19</td>
</tr>
<tr>
<td>(Js (a^{+}b^{+}))</td>
<td>100.0</td>
<td>80</td>
</tr>
<tr>
<td>(K_{b})</td>
<td>Exceedingly rare</td>
<td></td>
</tr>
</tbody>
</table>

Biotest Seraclone® Anti-\(\kappa\) Blood Group Reagent is used to test for the presence or absence of the \(\kappa\) antigen. Biotest Seraclone® Anti-\(\kappa\) is used principally in the resolution of antibody problems or in family studies.

Principle of the Test
The test principle is hemagglutination. The antibodies in Seraclone® Anti-\(\kappa\) (KEL2) bind to the \(\kappa\) antigen on red blood cells and cause an antigen-antibody reaction visible as red blood cell agglutination.

Reagent
As the reactive component Anti-\(\kappa\) (KEL2) contains a murine monoclonal antibody of the immunoglobulin class IgM. They are derived from hybridoma cell lines which are created by fusing mouse antibody producing B lymphocytes with mouse myeloma cells and demonstrate consistent specificity and reproducibility characteristic for monoclonal antibodies.

Antibodies are diluted in MES buffer pH 5.2, bovine albumin, macromolecular potentiators and EDTA.

Seraclone® Anti-\(\kappa\) (KEL2)  clone Lk1 (IgM)

Preservative: 0.1% sodium azide

Precautions
- For In-vitro diagnostic use.
- Store at 2 to 8°C.
- Do not use beyond the expiration date.
- Do not use if turbid.
- Use only phosphate buffered saline for suspension.
- Handle and dispose of reagents as potentially infectious.
- Caution: Do not pipette by mouth. The absence of murine viruses has not been determined.
- Caution: This product contains Natural Rubber Latex Which May Cause Allergic Reactions.
- Warning: Contains sodium azide (Na\(\text{N}_3\)), which may react with lead or copper plumbing to form explosive azides. If discarded in the sink, flush with large amounts of water to prevent the build-up of explosive metal azides.
- The bovine albumin used for the production of this reagent is sourced from donor animals of US origin that have been inspected and certified by US Veterinary Service inspectors to be disease-free.

Specimen Collection
Fresh samples of clotted, EDTA or citrate anticoagulated whole blood collected following general blood sampling guidelines are acceptable. The specimen should be tested as soon as possible after collection. If testing is delayed, EDTA and clotted specimens should be stored at 2 to 8°C, citrated specimens (donor segments) at 1 to 6°C.

Blood specimens exhibiting gross hemolysis or contamination should not be used.

Clotted samples or those collected in EDTA may be tested within ten days from collection. Donor blood stored in citrate anticoagulant may be tested until the expiration date of the donor unit.

Materials
Materials provided
- Seraclone® Anti-\(\kappa\) (KEL2)

Materials required but not provided
- Pipettes (drop volume 40 to 50 μl)
- Phosphate Buffered Saline (PBS) pH 7.3 ± 0.2, DO NOT use isotonic saline
- Glass tubes 10 x 75mm or 12 x 75mm
- Serological centrifuge
- Interval timer
- Markers
- Optical aid (optional). The use of an optical aid for agglutination reading must be validated by the user.

Test Procedure
Tube test
1. Prepare a 2 to 5% suspension of red blood cells to be tested in PBS pH 7.3 ± 0.2.
2. Place two drops reagent into an appropriately labeled tube.
3. Add two drops of red blood cell suspension into the tube and mix.
4. Incubate at room temperature (20 to 24°C) for 5 minutes.
5. Centrifuge for 10 seconds at 800 -1000 x g.
6. Gently dislodge red blood cell button and observe for agglutination.
7. Record results.

Stability of the Reaction
Following centrifugation, all tube tests should be read immediately and results interpreted without delay. Time delays may cause a dissociation of the antigen-antibody complexes resulting to false negative or more often weak positive reactions.

Quality Control
The reactivity of all blood typing reagents should be confirmed by testing with known positive and negative red blood cells on each day of use. To confirm the reactivity or specificity of Biotest Monoclonal Anti-\(\kappa\) Blood Grouping Reagent, it should be tested with antigen-positive (preferably from heterozygous individuals) and antigen-negative red blood cells, respectively. The reagent is satisfactory for use if it reacts only with antigen-positive red blood cells. It is recommended that a positive and a negative control be performed in parallel with testing.
Interpretation of results
Agglutination of the red blood cells is a positive result and indicates the presence of the corresponding antigen. No agglutination is a negative result and indicates the absence of the corresponding antigen. An agglutination viewer may facilitate the reading of tube tests (as recommended by the AABB Technical Manual, 15th edition). Frequencies in the population are listed in the "Summary" section.

Limitations
- Red blood cells from individuals of the Kell phenotype K ñ Kp (a+b+) show a substantially weakened expression of ñ antigen.
- Kell antigen expression may be dramatically weakened in some cases of Chronic Granulomatous Disease.
- Tube tests should be read by a "tip and roll" procedure. Excessive agitation may disrupt weak agglutination and produce false negative results.
- Samples with a positive direct antiglobulin test, cold agglutinins, or rouleaux formation may show false positive results in testing with monoclonal antibodies. Results on these samples must be interpreted with caution. False positive results or reaction suspected to be due to cold agglutinins should be resolved according to in-house procedures. It is recommended that an appropriate control be tested in parallel.
- Stored red blood cells may exhibit weaker reactions.
- Samples prepared with isotonic saline will give invalid results.
- Some conditions that may cause false positive results are:
  - Contamination of sample or reagents
  - Autoantibodies
  - Improper storage or preparation of red blood cells
  - Antibodies to antibiotics or other reagents
  - Cold Antibodies

Specific Performance Characteristics
Testing is performed in accordance with FDA recommended methods. The final release testing is performed according to the product specific SOPs. Each lot of Biotest Blood Group Reagent is tested in the Quality control by package insert method against a panel of antigen positive red blood cells (heterozygous antigen expression and if possible weakened antigen expression) to insure suitable reactivity. The products meet FDA potency requirements. The specificity testing for the presence of contaminating antibodies is performed according to the product specific SOPs. For the product performance it is necessary to adhere to the recommended method in the instructions for use.

The performance of the Biotest Anti-ñ was confirmed against a FDA approved reference reagent in a Multi Center Field Trial. Of the 390 samples tested only 2 samples were ñ (Cellano) antigen negative. Due to the frequency of the Cellano antigen being 100% for Blacks and 99.8% for Caucasians this is the expected rate of ñ negative samples.

For Technical Support or further product information, contact Biotest Diagnostics Corporation at 800-522-0090.

Note
Each facility should verify the optimum spin time for the specific centrifuge in use. Manual techniques are to be performed according to the manufacturer’s instructions. Each deviation from these instructions is the sole responsibility of the user. Used tests must be discarded as hazardous material. Manage waste according to local, state and national regulations.

Glossary of Symbols

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Definition</th>
<th>Symbol</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOT</td>
<td>Batch Code</td>
<td>IVD</td>
<td>In vitro diagnostic medical device</td>
</tr>
<tr>
<td>!</td>
<td>Caution, consult accompanying documents</td>
<td>I</td>
<td>Consult instructions for use.</td>
</tr>
<tr>
<td>⦿</td>
<td>Manufacturer</td>
<td>⦿</td>
<td>Use by YYYY-MM-DD</td>
</tr>
<tr>
<td>⦿</td>
<td>Contains sufficient quantity for &lt;n&gt; tests.</td>
<td>REF</td>
<td>Catalog number</td>
</tr>
<tr>
<td>⦿</td>
<td>Temperature limitation</td>
<td>VOL</td>
<td>Volume</td>
</tr>
</tbody>
</table>

Bibliography